Results 1 to 10 of about 394,896 (189)

Acute Myeloid Leukemia

HemaSphere, 2019
Acute myeloid leukemia (AML) occurs with a frequency of 3.5/1,000,000/year cases. AML patients have an invasion of diseased cells (blasts) medullary insufficiency, microenvironmental dysfunction, defects in the proliferation and function of the remaining
Hartmut Döhner, Daniel J. Weisdorf, Clara D. Bloomfield   +2 more
semanticscholar   +4 more sources

International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

Blood, 2022
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology.
D. Arber, A. Orazi, R. Hasserjian, M. Borowitz, K. Calvo, H. Kvasnicka, Sa A. Wang, A. Bagg, T. Barbui, S. Branford, C. Bueso-Ramos, J. Cortes, P. Dal Cin, C. Dinardo, H. Dombret, E. Duncavage, B. Ebert, E. Estey, F. Facchetti, K. Foucar, N. Gangat, U. Gianelli, L. Godley, N. Goekbuget, J. Gotlib, E. Hellström-Lindberg, G. Hobbs, R. Hoffman, E. Jabbour, J. Kiladjian, R. Larson, M. L. Le Beau, M. Loh, B. Löwenberg, E. Macintyre, L. Malcovati, C. Mullighan, C. Niemeyer, O. Odenike, S. Ogawa, A. Órfão, E. Papaemmanuil, F. Passamonti, K. Porkka, C. Pui, J. Radich, A. Reiter, M. Rozman, M. Rudelius, M. Savona, C. Schiffer, Annette Schmitt-Graeff, A. Shimamura, J. Sierra, W. Stock, R. Stone, M. Tallman, J. Thiele, H. Tien, A. Tzankov, A. Vannucchi, P. Vyas, A. Wei, O. Weinberg, A. Wierzbowska, M. Cazzola, H. Döhner, A. Tefferi   +67 more
semanticscholar   +1 more source

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers

eJHaem, 2021
Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies.
Emma Hernlund, Josefine Redig, Björn Paulsson, Åsa Rangert Derolf, Martin Höglund, Simona Vertuani, Gunnar Juliusson   +6 more
doaj   +1 more source

Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]

Einstein (São Paulo), 2011
Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman, Fabio Pires de Souza Santos, Belinda Simões, Elias Hallack Atta, Fernando Callera, Jane de Almeida Dobbin, Éderson Roberto Mattos, Angelo Atalla, Angelo Maiolino, Maria Aparecida Zanichelli, Cristiane Fração Diefenbach, Marcia Torresan Delamain, Nelson Hamerschlak   +12 more
doaj   +3 more sources

Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding.
S. Shimony, Maximilian F. Stahl, R. Stone   +2 more
semanticscholar   +1 more source

Recent advances in targeted therapies in acute myeloid leukemia

Journal of Hematology & Oncology, 2023
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell ...
R. Bhansali, K. Pratz, Catherine Lai
semanticscholar   +1 more source

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2023
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.
D. Pollyea, J. Altman, R. Assi, D. Bixby, A. Fathi, J. Foran, I. Gojo, Aric Hall, B. Jonas, Ashwin Kishtagari, J. Lancet, L. Maness, J. Mangan, G. Mannis, G. Marcucci, A. Mims, Kelsey Moriarty, Moaath K. Mustafa Ali, Jadee L. Neff, R. Nejati, R. Olin, M. Percival, A. Perl, Amanda C. Przespolewski, D. Rao, F. Ravandi, R. Shallis, P. Shami, E. Stein, R. Stone, K. Sweet, Swapna Thota, G. Uy, P. Vachhani, Carly J Cassara, Deborah A. Freedman-Cass, Katie Stehman   +36 more
semanticscholar   +1 more source

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

New England Journal of Medicine, 2022
BACKGROUND The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia ...
P. Montesinos, C. Récher, S. Vives, E. Zarzycka, Jianxiang Wang, Giambattista Bertani, M. Heuser, R. Calado, A. Schuh, S. Yeh, S. Daigle, J. Hui, S. Pandya, D. Gianolio, S. de Botton, H. Döhner   +15 more
semanticscholar   +1 more source

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Haematologica, 2019
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou, Jessie Yiying Quah, Yvonne Ng, Jing-Yuan Chooi, Sabrina Hui-Min Toh, Baohong Lin, Tuan Zea Tan, Hiroki Hosoi, Motomi Osato, Qihui Seet, A.G. Lisa Ooi, Bertil Lindmark, Mark McHale, Wee-Joo Chng   +13 more
doaj   +1 more source

Acute myeloid leukemia: current progress and future directions

Blood Cancer Journal, 2021
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
H. Kantarjian, T. Kadia, C. Dinardo, N. Daver, G. Borthakur, E. Jabbour, G. Garcia-Manero, M. Konopleva, F. Ravandi   +8 more
semanticscholar   +1 more source